Oxiperomide|CAS 5322-53-2|DC Chemicals

Cas No.:	5322-53-2
Chemical Name:	1-1-(2-phenoxyethyl)piperidin-4-yl-2,3-dihydro-1H-1,3-benzodiazol-2-one
Synonyms:	2H-Benzimidazol-2-one,1,3-dihydro-1-[1-(2-phenoxyethyl)-4-piperidinyl]-;3-[1-(2-phenoxyethyl)piperidin-4-yl]-1H-benzimidazol-2-one;1-(1-(2-phenoxyethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one;1-[1-(2-phenoxyethyl)piperidin-4-yl]-1,3-dihydro-2h-benzimidazol-2-one;1-[1-(2-phenoxy-ethyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one;Oxiperomida;Oxiperomide;Oxiperomidum;Peromide;R-4714;1-1-(2-phenoxyethyl)piperidin-4-yl-2,3-dihydro-1H-1,3-benzodiazol-2-one;NSC 313681;NSC313681;PDSP2_000049;1-(1-(2-phenoxyethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one;OXIPEROMIDE [INN];UNII-WRO75M6RW2;BDBM50388674;NSC-313681;Oxiperomidum [INN-Latin];AKOS008293760;SMR001831487;HY-119638;D02676;NS00123893;L000881;Z130192198;{1-[1-(2-Phenoxyethyl)-4-piperidyl]-2-benzimidazolinone};2H-Benzimidazol-2-one, 1,3-dihydro-1-(1-(2-phenoxyethyl)-4-piperidinyl)-;3-[1-(2-phenoxyethyl)-4-piperidyl]-1H-benzimidazol-2-one;MLS003115925;Q21547163;2-Benzimidazolinone, 1-[1-(2-phenoxyethyl)-4-piperidyl]-;1-(1-(2-Phenoxyethyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one;2-Benzimidazolinone, 1-(1-(2-phenoxyethyl)-4-piperidyl)-;Oxiperomida [INN-Spanish];CHEMBL2059304;OXIPEROMIDE [USAN];1-(1-(2-Phenoxyethyl)-4-piperidyl)-2-benzimidazolinone;Oxiperomide (USAN/INN);2H-Benzimidazol-2-one,3-dihydro-1-[1-(2-phenoxyethyl)-4-piperidinyl]-;PDSP1_000049;1-(1-(2-phenoxyethyl)piperidin-4-yl)-1h-benzo[d]imidazol-2(3h)-one;MLS006011550;2-Benzimidazolinone, {1-[1-(2-phenoxyethyl)-4-piperidyl]-};Oxiperomide [USAN:INN];EN300-1266076;SCHEMBL123291;5322-53-2;WRO75M6RW2;CS-0077190;2H-Benzimidazol-2-one, 1, {3-dihydro-1-[1-(2-phenoxyethyl)-4-piperidinyl]-};1-[1-(2-Phenoxyethyl)-4-piperidyl]-2-benzimidazolinone;SMR004703316;DTXSID30201306;R 4714;1-[1-(2-phenoxyethyl)piperidin-4-yl]-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES:	C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCOC4=CC=CC=C4
Formula:	C₂₀H₂₃N₃O₂
M.Wt:	337.41552
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

COA

MSDS

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.